ARTICLE | Company News
Noxxon, Pfizer deal
March 27, 2006 8:00 AM UTC
Noxxon granted PFE an exclusive worldwide license to develop and commercialize NOX-B11, a preclinical ghrelin receptor antagonist, to treat obesity. The compound, which was developed using Noxxon's ...